Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

1. Upadacitinib (Rinvoq) - rheumatoid arthritis

Upadacitinib (Rinvoq) - rheumatoid arthritis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2020 Health Canada - Drug and Health Product Register

2. A randomized, double-blind, placebo-controlled clinical trial, evaluating the garlic supplement effects on some serum biomarkers of oxidative stress, and quality of life in women with rheumatoid arthritis Full Text available with Trip Pro

A randomized, double-blind, placebo-controlled clinical trial, evaluating the garlic supplement effects on some serum biomarkers of oxidative stress, and quality of life in women with rheumatoid arthritis A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Evaluating the Garlic Supplement Effects on Some Serum Biomarkers of Oxidative Stress, and Quality of Life in Women With Rheumatoid Arthritis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Int J Clin Pract Actions . 2020 Mar 11;e13498. doi: 10.1111/ijcp.13498. Online ahead of print. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Evaluating the Garlic Supplement Effects on Some Serum Biomarkers of Oxidative Stress, and Quality of Life in Women With Rheumatoid Arthritis , , Affiliations Expand

2020 EvidenceUpdates

3. Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial

Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial Two-year Cost-Effectiveness of Different COBRA-like Intensive Remission Induction Schemes in Early Rheumatoid Arthritis: A Piggyback Study on the Pragmatic Randomised Controlled CareRA Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Ann Rheum Dis Actions . 2020 May;79(5):556-565. doi: 10.1136/annrheumdis-2019-216874. Epub 2020 Apr 2. Two-year Cost-Effectiveness of Different COBRA-like Intensive Remission Induction Schemes in Early Rheumatoid Arthritis: A Piggyback Study on the Pragmatic Randomised Controlled CareRA Trial , , , , , , , Affiliations Expand Affiliations 1

2020 EvidenceUpdates

4. Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery

Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery Immunosuppression and the Risk of Readmission and Mortality in Patients With Rheumatoid Arthritis Undergoing Hip Fracture, Abdominopelvic and Cardiac Surgery - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Ann Rheum Dis Actions . 2020 May;79(5):573-580. doi: 10.1136/annrheumdis-2019-216802. Epub 2020 Mar 24. Immunosuppression and the Risk of Readmission and Mortality in Patients With Rheumatoid Arthritis Undergoing Hip Fracture, Abdominopelvic and Cardiac Surgery , , , , , , , , Affiliations Expand Affiliations 1 Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA

2020 EvidenceUpdates

5. Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis

Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis Conventional Versus Ultrasound Treat to Target: No Difference in Magnetic Resonance Imaging Inflammation or Joint Damage Over 2 Years in Early Rheumatoid Arthritis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Rheumatology (Oxford) Actions . 2020 Jan 30;kez674. doi: 10.1093/rheumatology/kez674. Online ahead of print. Conventional Versus Ultrasound Treat to Target: No Difference in Magnetic Resonance Imaging Inflammation or Joint Damage Over 2 Years in Early Rheumatoid Arthritis , , , , , , , , , , Collaborators, Affiliations Expand Collaborators

2020 EvidenceUpdates

6. Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors Full Text available with Trip Pro

Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors Risk of Breast Cancer Before and After Rheumatoid Arthritis, and the Impact of Hormonal Factors - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S (...) Permalink Copy Page navigation Ann Rheum Dis Actions . 2020 Mar 11;annrheumdis-2019-216756. doi: 10.1136/annrheumdis-2019-216756. Online ahead of print. Risk of Breast Cancer Before and After Rheumatoid Arthritis, and the Impact of Hormonal Factors , , , Affiliations Expand Affiliations 1 Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden hjalmar.wadstrom@ki.se. 2 Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet

2020 EvidenceUpdates

7. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs Full Text available with Trip Pro

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field.An international task force considered new evidence supporting or contradicting previous recommendations and novel therapies and strategic insights based on two systematic literature

2020 EvidenceUpdates

8. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis Full Text available with Trip Pro

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis To perform a systematic literature review (SLR) concerning the safety of synthetic (s) and biological (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis (RA).An SLR of observational studies comparing safety outcomes of any DMARD

2020 EvidenceUpdates

9. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis Full Text available with Trip Pro

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis To inform the 2019 update of the European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA).A systematic literature research (SLR) to investigate the efficacy of any disease-modifying antirheumatic drug (DMARD) (conventional synthetic (cs)DMARD, biological (b

2020 EvidenceUpdates

10. Janus Kinase Inhibitors and Biosimilars for Rheumatoid Arthritis: Effectiveness and Value

Janus Kinase Inhibitors and Biosimilars for Rheumatoid Arthritis: Effectiveness and Value ©Institute for Clinical and Economic Review, 2020 Janus Kinase Inhibitors and Biosimilars for Rheumatoid Arthritis: Effectiveness and Value Final Evidence Report and Meeting Summary January 9, 2020 Prepared for ©Institute for Clinical and Economic Review, 2020 Page i Final Evidence Report: JAK Inhibitors and Biosimilars for RA None of the above authors disclosed any conflicts of interest. DATE (...) OF PUBLICATION: January 9, 2020 How to cite this document: Tice J, Kumar V, Chapman R, Walsh J, Herron-Smith S, Cianciolo L, Bradt P, Pearson S. Janus Kinase Inhibitors and Biosimilars for Rheumatoid Arthritis. Institute for Clinical and Economic Review, January 9, 2020. https://icer-review.org/material/ra-update-evidence- report/. Jeffrey A. Tice served as the lead author for the report, led the systematic review and authorship of the comparative clinical effectiveness section, and wrote the background

2020 California Technology Assessment Forum

11. Upadacitinib (Rinvoq) - Rheumatoid arthritis

Upadacitinib (Rinvoq) - Rheumatoid arthritis Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Classified as public by the European Medicines Agency EMA/582949/2019 EMEA/H/C/004760 (...) Rinvoq (upadacitinib) An overview of Rinvoq and why it is authorised in the EU What is Rinvoq and what is it used for? Rinvoq is a medicine for treating adults with rheumatoid arthritis, a disease that causes inflammation of the joints. Rinvoq is used for moderate or severe rheumatoid arthritis that cannot be controlled well enough with disease-modifying anti-rheumatic medicines or if the patient cannot take these medicines. It can be used on its own or with methotrexate, another medicine

2020 European Medicines Agency - EPARs

12. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study Full Text available with Trip Pro

Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study Overall Infection Risk in Rheumatoid Arthritis During Treatment With Abatacept, Rituximab and Tocilizumab; An Observational Cohort Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other (...) characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Rheumatology (Oxford) Actions 2019 Nov 25 [Online ahead of print] Overall Infection Risk in Rheumatoid Arthritis During Treatment With Abatacept, Rituximab and Tocilizumab; An Observational Cohort Study , , , , , , , Affiliations Expand Affiliations 1 DANBIO and Copenhagen

2020 EvidenceUpdates

13. A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis Full Text available with Trip Pro

A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis 3-hydroxy-3-methylglutaryl coenzyme-A (HMG Co-A) reductase inhibitors (statins) are standard treatment for hyperlipidaemia. In addition to lipid-lowering abilities, statins exhibit multiple anti-inflammatory effects. The objectives of this study were to determine whether treatment of patients with RA with lovastatin decreased CRP or reduced disease

2019 EvidenceUpdates

14. Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study Full Text available with Trip Pro

Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study To examine all-cause and cardiovascular disease (CVD) mortality in consecutive cohorts of patients with incident RA, compared with population comparators.The Oslo RA register inclusion criteria were diagnosis of RA (1987 ACR criteria) and residency in Oslo. Patients with disease onset 1994-2008 and 10 matched comparators for each case were linked

2019 EvidenceUpdates

15. Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study (Abstract)

Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study Abatacept, a biologic DMARD, was associated with respiratory adverse events in a small subgroup of RA patients with chronic obstructive pulmonary disease (COPD) in a trial. Whether this potential risk is specific to abatacept or extends to all biologics and targeted synthetic DMARDs (tsDMARDs) is unclear. We assessed the risk of adverse respiratory events

2019 EvidenceUpdates

16. Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network Full Text available with Trip Pro

Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network To examine associations between function, quality of life and structural outcomes in patients achieving remission vs low disease activity in early RA.Demographic, clinical and radiographic variables were collected at baseline and then annually from the Early Rheumatoid Arthritis Study (ERAS) and Early Rheumatoid Arthritis Network (ERAN) inception cohorts

2019 EvidenceUpdates

17. Upadacitinib (Rinvoq) - rheumatoid arthritis

Upadacitinib (Rinvoq) - rheumatoid arthritis CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 211675Orig1s000 CLINICAL REVIEW(S) Clinical Review Keith M Hull, MD, PhD NDA 211675 RINVOQ (upadacitinib) CLINICAL REVIEW Application Type NDA Application Number(s) 211675 Priority or Standard Priority Submit Date(s) 18 Dec 2018 Received Date(s) 18 Dec 2018 PDUFA Goal Date 18 Aug 2019 Division/Office Division of Pulmonary, Allergy and Rheumatology Products Reviewer Name(s) Keith M Hull, MD (...) , PhD Review Completion Date 17 May 2019 Established/Proper Name Upadacitinib (Proposed) Trade Name RINVOQ Applicant AbbVie Inc Dosage Form(s) 15 mg extended release tablets Applicant Proposed Dosing Regimen(s) 15 mg orally administered QD Applicant Proposed Indication(s)/Population(s) Recommendation on Regulatory Action Approval Recommended Indication(s)/Population(s) (if applicable) Treatment of adults with moderately to severely active rheumatoid arthritis who had an inadequate response

2019 FDA - Drug Approval Package

18. Triple Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for the Management of Rheumatoid Arthritis

Triple Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for the Management of Rheumatoid Arthritis Triple Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for the Management of Rheumatoid Arthritis | CADTH.ca Find the information you need Triple Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for the Management of Rheumatoid Arthritis Triple Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for the Management of Rheumatoid Arthritis Last (...) updated: March 26, 2019 Project Number: RC1087-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the cost-effectiveness of triple conventional synthetic disease-modifying anti-rheumatic drugs compared with other pharmacologic options for the management of rheumatoid arthritis? Key Message Two relevant publications comprising cost-effectiveness analyses were identified; one involved patients with rheumatoid arthritis (RA) that could

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

19. Upadacitinib (TBC) - Arthritis, Rheumatoid

Upadacitinib (TBC) - Arthritis, Rheumatoid upadacitinib | CADTH.ca Find the information you need upadacitinib upadacitinib Last Updated: October 4, 2019 Result type: Reports Project Number: SR0614-000 Product Line: Generic Name: upadacitinib Brand Name: TBC Manufacturer: AbbVie Indications: Arthritis, Rheumatoid Manufacturer Requested Reimbursement Criteria 1 : Upadacitinib to be listed for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded (...) recommendation, if applicable. Key Milestones 2 Call for patient input posted May 31, 2019 Patient group input closed July 22, 2019 Clarification: - Patient input submission received from the Arthritis Consumer Experts, Canadian Arthritis Patient Alliance (CAPA) & The Arthritis Society Patient input summary sent for review to patient input groups July 30, 2019 Patient group comments on input summary closed August 07, 2019 Clarification: - Patient input summary feedback received Submission received July 04

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

20. Olumiant - baricitinib - Arthritis, Rheumatoid

Olumiant - baricitinib - Arthritis, Rheumatoid baricitinib | CADTH.ca Find the information you need baricitinib baricitinib Last Updated: September 12, 2019 Result type: Reports Project Number: SR0597-000 Product Line: Generic Name: baricitinib Brand Name: Olumiant Manufacturer: Eli Lilly Canada Inc. Indications: Arthritis, Rheumatoid Manufacturer Requested Reimbursement Criteria 1 : In combination with methotrexate (MTX), indicated for reducing the signs and symptoms of moderate to severe (...) rheumatoid arthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs).Olumiant may be used as monotherapy in cases of intolerance to MTX. Submission Type: New Project Status: Complete Biosimilar: No Companion Diagnostics: No Date Recommendation Issued: August 2, 2019 Recommendation Type: Reimburse with clinical criteria and/or conditions Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review